ABLAVAR® is the first and only contrast agent approved by the FDA for MRA evaluation of aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease. ABLAVAR® is a blood-pool contrast agent that reversibly binds to albumin. This provides an expanded imaging window of up to 1 hour, which allows you to obtain bright, high-resolution steady-state images in addition to finely detailed first-pass images. ABLAVAR® makes the MRA examination more convenient because it is less dependent on bolus dynamics.